Skip to content
Sign in
Venture capitalBacked 1 network startup

WeVentures

Korean investor with an empty profile; participated in BILIX's Series A (acute kidney injury drug).

South Korea
Ticket
—Not published
Assets under management
—
Founded
—
Stages
—
Network startups backed
1
Co-investors
5most often with DS Asset Management

How they invest

No thesis is recorded. The BILIX Series A (with KDDF, IBK, Solbrain Holdings and others) suggests interest in Korean biotech; nothing else is documented.

Stage and ticket

Unknown; Series A participation.

Geography

Unknown; Korea-based.

What makes them say yes

  • Korean biotech (inferred)
  • Unknown
  • Unknown

Red flags

  • Thesis undocumented
  • Unknown

Sectors

Not published

Stages

Not published

Geographies

Not published

How to approach

BILIX's founders are the warm path.

Portfolio

1 network startup · no other company

Single recorded deal.

Gaps in the portfolio

  • Thesis unknown

Network startups

  • BILIXSWC 2026 Finalist

    KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

    South Korea · Biotech & life sciences

Network startups that fit

3 analysed

HKUST polymer-therapeutics platform entering the clinic in dry eye, with osteoarthritis and aesthetics as follow-on indications.

HKUST polymer therapeutics with a first-in-human trial authorised: Asian clinical-stage biotech like BILIX.

25%confidence

Evidence from the records

  • “Polymer-based therapeutics (ophthalmology, osteoarthritis, regenerativ”
  • “Series A”
Intro path
BILIX founders.
First step
Ask BILIX about WeVentures' biotech mandate.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Co-investors

Most often with DS Asset Management, Estech Pharma, and IBK (Industrial Bank of Korea)

Sources

  1. 1thevc.kr/bilix/fundings

Profile compiled from public sources. Unknown fields are left empty rather than estimated.